Votrient (pazopanib
hydrochloride) has been listed
on the Pharmaceutical Benefits
Scheme (PBS), from 01 Mar.
The medication has been listed
for advanced soft tissue sarcoma
in patients who received prior
chemotherapy including an
anthracycline treatment.
This PBS listing adds to Votrient’s
existing listing for treatment of
advanced and/or metastatic renal
cell carcinoma (RCC).The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.